ENTA — Enanta Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $306.94m
- $104.17m
- $67.64m
- 37
- 13
- 95
- 46
Annual cashflow statement for Enanta Pharmaceuticals, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -36.2 | -79 | -122 | -134 | -116 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 16.1 | 19 | 27.2 | 20.3 | 27.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 12.9 | -13.7 | 6.79 | 8.02 | 7.13 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 7.09 | -70 | -84.8 | -103 | -78.8 |
| Capital Expenditures | -1.45 | -0.75 | -2.13 | -9.06 | -17.9 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 21.3 | 37.7 | 57 | -44.5 | 76.2 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 19.8 | 37 | 54.9 | -53.6 | 58.2 |
| Financing Cash Flow Items | -1.5 | -0.534 | -1.23 | 196 | -27.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 8.98 | 3.08 | 20 | 198 | -27.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 35.9 | -29.9 | -9.85 | 41.4 | -48.2 |